Theravance Biopharma Inc TBPH

NAS: TBPH | ISIN: KYG8807B1068 14/11/2024

9,570 USD (-1,14%)

(-1,14%) 14/11/2024

Grafiek Theravance Biopharma Inc

Grafiek Theravance Biopharma Inc

1 dag1d -1,14%
1 week1w 7,05%
1 maand1m 11,28%
3 maanden3m 16,00%
6 maanden6m -2,84%
1 jaar1j -6,45%
5 jaar5j -46,36%

Theravance Biopharma Inc in het nieuws

Toon enkel gratis nieuws

27 augustus 2024 · Theravance Biopharma to Participate in an Upcoming Investor Conference · Persbericht

5 augustus 2024 · Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update · Persbericht

25 juli 2024 · Theravance Biopharma to Participate in an Upcoming Investor Conference · Persbericht

22 juli 2024 · Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 · Persbericht

13 mei 2024 · Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update · Persbericht

9 mei 2024 · Theravance Biopharma to Participate in an Upcoming Investor Conference · Persbericht

29 april 2024 · Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 · Persbericht

10 april 2024 · Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 · Persbericht

26 februari 2024 · Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update · Persbericht

22 februari 2024 · Theravance Biopharma to Participate in an Upcoming Investor Conference · Persbericht

Profiel Theravance Biopharma Inc

Fabricage van farmaceutische preparaten

Farmaceutische producten: Andere

Gezondheidstechnologie

CEO: Rick Winningham

Werknemers: 270

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe